News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Kilkari programme aims to offer weekly services, timely accessible, accurate and pertinent 72 audio messages through IVRS about reproductive maternal, neonatal and child health care
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company will be managing orders and warehouse operations for Little's, Lacto-calamine, Tri-activ, I-feel, Ourdaily, and Sloan's through the Unicommerce platform
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated
